|
Cell Signaling Technology Inc
p rpb1 ctd s2 ![]() P Rpb1 Ctd S2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ctd-ser2-p/Phospho-Rpb1+CTD+(Ser2)+Rabbit+mAb/pmc13771394-267-14-19 Average 96 stars, based on 1 article reviews
p rpb1 ctd s2 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
p ser 2 rna polymerase ii ![]() P Ser 2 Rna Polymerase Ii, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ctd-ser2-p/Phospho-Rpb1+CTD+(Ser2)+Rabbit+mAb/pm41896195-220-28-25 Average 96 stars, based on 1 article reviews
p ser 2 rna polymerase ii - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
anti p rnap ii ctd ser2 ![]() Anti P Rnap Ii Ctd Ser2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ctd-ser2-p/pm41589601-365-15-4 Average 86 stars, based on 1 article reviews
anti p rnap ii ctd ser2 - by Bioz Stars,
2026-11
86/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
p rpb1 ctd ![]() P Rpb1 Ctd, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ctd-ser2-p/Phospho-Rpb1+CTD+(Ser2)+Rabbit+mAb/pmc12627336-73-53-55 Average 96 stars, based on 1 article reviews
p rpb1 ctd - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
4735s polii rpb1 ctd 4h8 cell signaling technology 2629s p akt phospho akt ser473 ![]() 4735s Polii Rpb1 Ctd 4h8 Cell Signaling Technology 2629s P Akt Phospho Akt Ser473, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ctd-ser2-p/Phospho-Rpb1+CTD+(Ser2%2F5)+Antibody/pmc12514485__BLOODA_ADV-2025-016511-mmc1-12-57-62 Average 93 stars, based on 1 article reviews
4735s polii rpb1 ctd 4h8 cell signaling technology 2629s p akt phospho akt ser473 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
anti p ser2 ![]() Anti P Ser2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ctd-ser2-p/Phospho-Rpb1+CTD+(Ser2)+Rabbit+mAb/10__1172_slash_jci193745-198-48-49 Average 96 stars, based on 1 article reviews
anti p ser2 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
pol ii p ser2 ![]() Pol Ii P Ser2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ctd-ser2-p/Phospho-Rpb1+CTD+(Ser2)+Rabbit+mAb/pmc12120090-397-83-88 Average 96 stars, based on 1 article reviews
pol ii p ser2 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
Journal: Advanced Science
Article Title: CDK12 Inhibition Against Group 3 Medulloblastoma With PROTAC or Molecular Glue Degrader: Resistance Mediated by Distinct Transporters and Effective Countermeasures
doi: 10.1002/advs.78794
Figure Lengend Snippet: All three classes of CDK12 inhibition therapy target G3‐MB effectively by suppressing transcription of DDR genes, oncogenic TFs, and translation initiation factors. (A) Dose‐response curves at 72 h of SR‐4835, BSJ‐4‐116, and THZ531 in G3‐MB, non‐G3‐MB, and normal cells. (B–D) After treating G3‐MB cell lines (D458, MB002, D425) with CDK12 inhibitors 0.1 µM SR4835, 0.2 µM THZ531, and 0.1 µM BSJ‐4‐116 for 20 h, the protein expression levels of P‐Rpb1‐S2, γH2A.X, MYC, and OTX2 were detected and quantified, with corresponding statistical graphs generated from the quantification data; meanwhile, the mRNA expression levels of MYC, OTX2, and DDR genes were also measured. (E–G) After treating D458 cells with 0.1 µM SR4835, 0.25 µM THZ531, and 0.1 µM BSJ‐4‐116, and MB002 cells with 0.1 µM SR4835, 0.2 µM THZ531, and 0.1 µM BSJ‐4‐116 for 20 h, the mRNA and protein expression levels of CDK12 and elF4A1 were measured and quantified, with corresponding statistical graphs generated. Data are shown as the means ± SD. Significance of gene expression levels between groups was determined by two‐way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Article Snippet: The antibodies used were as follows: β‐tubulin (ab6046, Abcam), CDK12 (11973S, CST; 26816‐1‐AP, Proteintech),
Techniques: Inhibition, Expressing, Generated, Gene Expression
Journal: Advanced Science
Article Title: CDK12 Inhibition Against Group 3 Medulloblastoma With PROTAC or Molecular Glue Degrader: Resistance Mediated by Distinct Transporters and Effective Countermeasures
doi: 10.1002/advs.78794
Figure Lengend Snippet: CCNK‐targeted molecular glue degrader SR‐4835 works synergistically with CDK9 inhibitor AZD4573 or BET inhibitor JQ1 against G3‐MB in vitro. (A–C) Cell viability (top) and combination index (CI, bottom) in D425 cells treated with SR‐4835 and AZD4573/JQ1 at the indicated concentrations, respectively. (D–I) Protein expression levels of multiple genes in D425 cells treated with 0.03 µM SR4835, 0.03 µM BSJ‐4‐116, 0.03 µM THZ531 combined with 0.005 µM AZD4573 or 0.7 µM JQ1 for 20 h, respectively, as well as the statistical analysis graph of protein expression levels. Data are shown as the means ± SD. Significance of gene expression levels between groups was determined by two‐way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Article Snippet: The antibodies used were as follows: β‐tubulin (ab6046, Abcam), CDK12 (11973S, CST; 26816‐1‐AP, Proteintech),
Techniques: In Vitro, Expressing, Analysis, Gene Expression
Journal: Journal of Advanced Research
Article Title: CDK8 mediated inflammatory microenvironment aggravates osteoarthritis progression
doi: 10.1016/j.jare.2025.01.017
Figure Lengend Snippet: CDK8 activates the NF-κB pathway and regulates the transcription of SASP. (A) Western blot assay was used to detect the expression levels of p-IκBα, IκBα, p-p65, and p65. (B) Immunoprecipitation was performed to assess the co-precipitation of CDK8 and p65 in C28/I2 cells treated with or without CDK8-IN-6. (C) Immunofluorescence co-localization was conducted to examine the co-localization of p65 and CDK8 in C28/I2 cells treated with IL-1β for 24 h. (D) C28/I2 cells were transfected with si-CDK8 or pCMV3-CDK8, followed by IL-1β treatment for 24 h, and then subjected to western blot analysis of nuclear and cytoplasmic proteins. (E-F) Dual-luciferase analysis demonstrated NF-κB's regulatory role in SASP transcriptional activation (E) and confirmed the direct binding sites of p65 in the promoters of the IL-6, IL-8, and MMP-13 genes (F), the statistical results indicating the significance of the differences between the truncated promoter groups and the full-length group. (G) Nucleic acid electrophoresis and (H) ChIP-qPCR further investigated the influence of CDK8 on the binding of p65 to SASP promoter region sites in C28/I2 cells. (I) Western blot assay was used to detect the expression levels of Rpb1 CTD, p-Rpb1 CTD (Ser2), and p-Rpb1 CTD (Ser5). Data are presented as mean ± SD; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, no significance; comparisons with the control group or as indicated.
Article Snippet: The primary antibodies used are listed as follows: Aggrecan (HuaBio, Cat. ET1704-57), COL2A1 (Abcam, Cat. ab34712), SOX9 (HuaBio, Cat. et1611-56), MMP3 (Abcam, Cat. ab52915), MMP13 (Abcam, Cat. ab39012), CDK8 (Proteintech, Cat. 22067–1-AP), p65 (CST, Cat. 8242), p-p65 (Affinity, Cat. AF2006), IκBα (CST, Cat. 4814), p-IκBα (CST, Cat. 2859), Rpb1 CTD (CST, Cat. 2629),
Techniques: Western Blot, Expressing, Immunoprecipitation, Immunofluorescence, Transfection, Luciferase, Activation Assay, Binding Assay, Nucleic Acid Electrophoresis, ChIP-qPCR, Control
Journal: Journal of Advanced Research
Article Title: CDK8 mediated inflammatory microenvironment aggravates osteoarthritis progression
doi: 10.1016/j.jare.2025.01.017
Figure Lengend Snippet: CDK8 and NF-κB are cooperatively recruited to SASP promoters, leading to elongation phosphorylation of the Rpb1 CTD. In C28/I2 cells transfected with si-NC or si-CDK8, with or without IL-1β treatment for one hour, (A–E) ChIP analysis shows the effects of CDK8 knockdown and IL-1β treatment on the binding of p65 (A), CDK8 (B), Rpb1 CTD (C), Rpb1 CTD phosphorylated at Ser5 (D), and Rpb1 CTD phosphorylated at Ser2 (E) to three SASP genes and a housekeeping gene. The gene diagrams are displayed at the top.
Article Snippet: The primary antibodies used are listed as follows: Aggrecan (HuaBio, Cat. ET1704-57), COL2A1 (Abcam, Cat. ab34712), SOX9 (HuaBio, Cat. et1611-56), MMP3 (Abcam, Cat. ab52915), MMP13 (Abcam, Cat. ab39012), CDK8 (Proteintech, Cat. 22067–1-AP), p65 (CST, Cat. 8242), p-p65 (Affinity, Cat. AF2006), IκBα (CST, Cat. 4814), p-IκBα (CST, Cat. 2859), Rpb1 CTD (CST, Cat. 2629),
Techniques: Phospho-proteomics, Transfection, Knockdown, Binding Assay
Journal: Nature Communications
Article Title: RNF20 links the DNA damage response and metabolic rewiring in lung cancer through HIF1α
doi: 10.1038/s41467-025-60223-4
Figure Lengend Snippet: a Schematic representation of the method for calculating Pol II pausing index (PI). b Genome tracks of merged Pol II RNA-Seq reads of control and Rnf20 + /- MLE12 cells at genes involved in glycolysis. c Log2 of the PI at genes upregulated, unchanged or downregulated upon Rnf20 LOF ( n = 3). d, e Venn diagram showing an overlap of genes with decreased PI and upregulation in Rnf20 + /- compared to control MLE12 cells ( d ) and GO analysis of the overlapping genes ( e ). f Log2 of the PI at HIF-1 signaling pathway (left) or EMT genes (right) in control and Rnf20 + /- MLE12 cells ( n = 3). g Ratio of the Pol II enrichment at the TSS and TTS of Scl2a1 , Eno1 and Pdk1 in control ( n = 3) and Rnf20 + /- lungs ( n = 5) determined by Pol II Chip-qPCR. TSS, Transcription Start Site; TTS, Transcription Termination Site. h Venn diagram showing the overlap of genes with decreased PI in Rnf20 + /- compared to control MLE12 cells and HIF1α-bound genes in A549 lung AD cells (left) and GO analysis of the overlap (right). i, j Genome tracks of merged Pol II ChIP-Seq reads of control, Rnf20 + /- and Rnf20 + /- MLE12 cells stably expressing shRNA against Hif1a ( i ) and PI at HIF1α-bound genes in lung A549 AD cells ( j , n = 2). k Chip-qPCR for RNA Pol II CTD-pSer2 (left) and CTD-pSer5 (right) at Scl2a1 , Ldha and Eno1 gene body in control, Rnf20 + /- MLE12 cells, or Rnf20 + /- MLE12 cells after shRNA mediated Hif1a silencing ( n = 3). Statistical analysis in ( c, f, g ) was performed using a two-tailed Student’s t-test. Multiple comparisons were performed using one-way ANOVA with Šídák’s ( j, k ) multiple comparisons test. Boxplots in ( c, f, j ) represent the minimum, 25 th percentile (Q1), median, 75 th percentile (Q3), and maximum of the Log2 PI in control, Rnf20 + /- MLE12 cells, or Rnf20 + /- MLE12 cells after shRNA-mediated Hif1a silencing. GO analysis in e and h was performed using Metascape (Version 3.5). Data are shown as mean ± SEM. ns, non-significant. ‘n’ indicates biological replicates.
Article Snippet: The nuclei were washed with cold PBS and centrifuged at 2500 g , 4 °C for 5 min. Chromatin was sheared using a Covaris Ultrasonicator (10% duty factor, 200 cycles, 75 A) for 6 min and the samples were clarified at 16,000 g for 15 min. Next, the extracts were pre-cleaned with 75 μl protein G beads for 2 h at 4 °C, then incubated with 0.5 μg Pol II antibody (14958S, Cell Signaling), 1 μg Pol II p-Ser5 (ab5131, Abcam), 1 μg
Techniques: RNA Sequencing, Control, ChIP-qPCR, ChIP-sequencing, Stable Transfection, Expressing, shRNA, Two Tailed Test
Journal: Nature Communications
Article Title: RNF20 links the DNA damage response and metabolic rewiring in lung cancer through HIF1α
doi: 10.1038/s41467-025-60223-4
Figure Lengend Snippet: a Immunohistochemistry of tissue samples from different types and grades of lung tumors from a tissue microarray stained with HIF1α, ENO1 and LDHA antibodies. Scale bars, 100 µm. b Pearson correlation (r) of the relative staining intensity (H-Score) of RNF20 and HIF1α (top panels), RNF20 and ENO1 (middle panels), and RNF20 and LDHA (bottom panels) in AD and SCLC patients, with a two-sided p-value computed using the t-distribution. n = 70 for AD; n = 22 for SCLC. c Schematic model of the function of RNF20 in lung SCLC and AD development. PNEC pulmonary neuroendocrine cell, AT1 alveolar type 1 cell, AT2 alveolar type 2 cell, RNAPII RNA polymerase II. The figure was created in BioRender .
Article Snippet: The nuclei were washed with cold PBS and centrifuged at 2500 g , 4 °C for 5 min. Chromatin was sheared using a Covaris Ultrasonicator (10% duty factor, 200 cycles, 75 A) for 6 min and the samples were clarified at 16,000 g for 15 min. Next, the extracts were pre-cleaned with 75 μl protein G beads for 2 h at 4 °C, then incubated with 0.5 μg Pol II antibody (14958S, Cell Signaling), 1 μg Pol II p-Ser5 (ab5131, Abcam), 1 μg
Techniques: Immunohistochemistry, Microarray, Staining